A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
Public ClinicalTrials.gov record NCT00051467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic cancer. TNFerade™ is a replication deficient adenovirus vector containing the gene for TNF-alpha controlled by a chemoradiation inducible promoter. This allows the expression of TNF-alpha to be greatest in the area receiving radiation. TNF-alpha is a cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. TNFerade™ Biologic is a novel way of selective delivery of TNF-alpha to tumor cells. TNFerade™ Biologic will be injected during five weekly injection sessions, concomitant with radiation and 5-FU. TNFerade™ Biologic will be administered by direct intratumoral injection using a percutaneous approach (PTA) or endoscopic ultrasound (EUS).
Study identification
- NCT ID
- NCT00051467
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Feb 23, 2012
United States locations
- U.S. sites
- 25
- U.S. states
- 18
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Moores Cancer Center | La Jolla | California | — | — |
| UCLA School of Medicine, Division of Hematology-Oncology | Los Angeles | California | — | — |
| UC Irvine Medical Center | Orange | California | — | — |
| University of Colorado Health Science Center Facility | Denver | Colorado | — | — |
| Georgetown, MedStar Research Institute | Washington D.C. | District of Columbia | — | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | — | — |
| Tampa General Hospital | Tampa | Florida | — | — |
| Winship Cancer Center, Emory University | Atlanta | Georgia | — | — |
| The Universtiy of Chicago Medical Center | Chicago | Illinois | — | — |
| St. James Hospital and Health Centers Comprehensive Cancer Institute | Olympia Fields | Illinois | — | — |
| Indiana University Medical Goup | Indianapolis | Indiana | — | — |
| Johns Hopkins Medical Center | Baltimore | Maryland | — | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | — | — |
| Wayne State University, Karmanos Cancer Institute | Detroit | Michigan | — | — |
| Research Medical Center | Kansas City | Missouri | — | — |
| Washington University | St Louis | Missouri | — | — |
| Beth Israel Medical Center, BI Cancer Center | New York | New York | — | — |
| Leo W. Jenkins Cancer Center | Greenville | North Carolina | — | — |
| Cancer Centers of the Carolinas | Greenville | South Carolina | — | — |
| Mary Crowley Medical Center | Dallas | Texas | — | — |
| Univeristy of Texas Southwestern Medical Center | Dallas | Texas | — | — |
| Baylor College of Medicine | Houston | Texas | — | — |
| Virginia Commonwealth University | Richmond | Virginia | — | — |
| Virginia Mason Medical Center | Seattle | Washington | — | — |
| University of Wisconsin, Division of Neoplastic Diseases & Related Disorders | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00051467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2012 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00051467 live on ClinicalTrials.gov.